Thermo Fisher Scientific Reports Strong Q3 2026 Results and Raises Full-Year Guidance
Thermo Fisher Scientific (TMO) delivered a robust third quarter in 2026, reporting revenue of $12.14 billion, a 9% increase year-over-year. Growth was primarily driven by strong performance in the pharma, biotech, and industrial sectors, with organic revenue growing by 6%. The company's adjusted EPS rose 15% to $6.68, benefiting from significant operating margin expansion of 120 basis points due to productivity gains. Following these results, management raised its full-year organic revenue growth guidance to 4% and increased its free cash flow expectations to between $7 billion and $7.5 billion. The company also benefited from a $60 million net impact from tariff refund recoveries. Strategic moves included the successful $1 billion divestiture of its microbiology business and ongoing investments in AI-enabled software for electron microscopy.
Tickers: $TMO
Topics: EPS Financial Guidance Revenue Growth Segment Performance
Read the full article at Motley Fool
Part of the story Equinix Reports Strong Q3 2026 Results and Raises Full-Year Guidance (49 articles)